MGRX Mangoceuticals
- 0.243
- -0.018-7.04%
- 0.246
- +0.003+1.19%
Mangoceuticals News
MangoRx Acquires Patent Portfolio For Total Of $20M Through Issuance Of 980K Of 6% Series C Convertible Preferred Shares
Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunc
Express News | Mangoceuticals Inc: Pursuant to Ppa, Company Agreed to Pay Intramont a Total of $20 Mln for Patent Portfolio
Express News | Mangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive Care
Mangoceuticals Files to Sell 30M Shares of Common Stock for Holders
Mangoceuticals Signs Securities Purchase Deal; Mexican Unit Enters Technical Deal With Emifarma
Mangoceuticals' (MGRX) said in a regulatory filing late Thursday that it has signed a securities purchase agreement to sell 1,500 shares of series B convertible preferred stock for approximately $1.7
Mangoceuticals Partners With Emifarma for ED Product Development
Express News | Mangoceuticals Subsidiary, Mangorx Mexico, Executes Technical Agreement With Mexican Pharmaceutical Manufacturer for Initial Development and Production of Its Mango Erectile Dysfunction (Ed) Products
This Mangoceuticals Insider Increased Their Holding In The Last Year
12 Consumer Staples Stocks Moving In Tuesday's After-Market Session
GainersFarmer Bros (NASDAQ:FARM) stock increased by 4.8% to $3.48 during Tuesday's after-market session. The company's market cap stands at $73.3 million. Pricesmart (NASDAQ:PSMT) stock moved upwards
Mangoceuticals Shareholders Back Strategic Moves at Special Meeting
Top Premarket Gainers
Taysha Gene Therapies (TSHA) shares surged almost 26% in recent Wednesday premarket activity a day after reporting a smaller 2023 net loss per share and higher revenue from the previous year. Mangoceu
MangoRx Launches 'PRIME' By MangoRx, Powered By Kyzatrex FDA Approved Oral Testosterone Replacement Therapy Treatment
The Dallas Based, Direct-to-Consumer Telemedicine Company Brings the FDA-Approved Oral Testosterone Replacement Therapy Treatment to the Telehealth MarketDallas, Texas, March 12, 2024 (GLOBE NEWSWIRE)
Express News | MangoRx Launches Direct-To-Clinics Sales Division
MangoRx Accepting Pre Orders For Its "PRIME", by MangoRx, Powered By Kyzatrex FDA Approved Oral Testosterone Replacement Therapy Product
The Dallas Based, Direct-to-Consumer Telemedicine Company to Offer 2 Months of Free 'PRIME' by MangoRx, Powered by Kyzatrex (a $498 value) for First 1,000 SubscribersDallas, Texas, Feb. 05, 2024 (GLOB
Mangoceuticals Races to Meet Nasdaq Equity Threshold
Mangoceuticals, Inc. Announces Pricing Of $1.2M Public Offering Of 4M Shares Of Common Stock At A Price Of $0.30 Per Share
Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products via a secure telemedicine platf
Wall Street Set to Open Narrowly Mixed Ahead of PMI, Industrial Production Data
US stocks looked set to open narrowly mixed Friday ahead of the flash December purchasing managers report and November industrial production. Dow Jones Industrial Average futures were off 0.1%, S&P 50
Investors Look to Keep Rally Going as US Futures Trend Higher Friday
US stock futures were trending higher in Friday's premarket ahead of the flash December purchasing managers report and November industrial production. Dow Jones Industrial Average futures were up 0.32
Top Premarket Decliners
Aadi Biosciences (AADI) shares sank 48% premarket Friday, a day after reporting an overall response rate of up to 26% in a tumor-agnostic trial assessing nab-sirolimus. Inno Holdings (INHD) shares plu
MANGOCEUTICALS TO INTRODUCE "PRIME", POWERED BY KYZATREX (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT
The Dallas Based, Direct-to-Consumer Telemedicine Company Secures Marketing Agreement with Marius Pharmaceuticals Bringing KYZATREX to the Telehealth Market as 'Prime' by MangoRx.
Analysis
Price Target
No Data
